• Deciphering Salidroside’s Mechanisms in Myocardial Hypoxia v

  2026-04-22

  This study comprehensively profiles proteomic and phosphoproteomic alterations in cardiomyocytes exposed to hypoxia and treated with salidroside, revealing key regulatory nodes in cell cycle and cytoskeleton stability. The findings offer mechanistic insight into salidroside’s protective effect against myocardial hypoxia and provide a resource for protein phosphorylation analysis in cardiovascular research.

• Energy Deficiency, ATG4B, and DNA Repair in Leukemia Progres

  2026-04-22

  This study uncovers how cellular energy deficiency drives the nuclear translocation of ATG4B, disrupting PRMT1-mediated DNA repair and accelerating acute myeloid leukemia (AML) progression. The findings provide new mechanistic insight into cancer metabolism and genome stability, offering a foundation for future research on metabolic vulnerabilities in hematologic malignancies.

• Dihydroethidium (DHE) in Redox Biology: Precision Superoxide

  2026-04-21

  Explore how Dihydroethidium (DHE) transforms intracellular reactive oxygen species measurement with unparalleled specificity, focusing on its critical role in cardiovascular disease and apoptosis research. This article uniquely bridges mechanistic insight and translational assay design, grounded in the latest peer-reviewed evidence.

• RG108: Precision DNA Methyltransferase Inhibition for Advanc

  2026-04-21

  Explore how RG108, a potent DNA methyltransferase inhibitor, advances epigenetic research by enabling precise gene regulation and demethylation strategies. This article uncovers practical assay insights, unique mechanistic features, and comparative protocols to guide experimental design.

• Neurotensin (CAS 39379-15-2): Advanced GPCR Trafficking Tool

  2026-04-20

  Discover how Neurotensin, a leading Neurotensin receptor 1 activator, advances GPCR trafficking mechanism studies and miRNA regulation in gastrointestinal cells. This article uniquely explores spectral interference and assay fidelity for translational research.

• Human Gastrin I Peptide: Catalyzing Organoid-Driven GI Resea

  2026-04-20

  This article provides translational researchers with mechanistic insights and strategic guidance on leveraging human Gastrin I peptide for advanced gastrointestinal pathway research, with a special focus on stem cell-derived organoid models. It integrates recent findings, competitive benchmarking, protocol recommendations, and a future outlook, offering a differentiated, evidence-backed resource beyond standard product listings.

• Concerted Screening Uncovers Combination Therapies for Pancr

  2026-04-19

  This study introduces a dual in vitro and in vivo screening platform for identifying effective drug combinations against pancreatic ductal adenocarcinoma (PDA). By leveraging Rgs16::GFP as a rapid biomarker and integrating BET bromodomain and HDAC inhibition strategies, the research demonstrates enhanced therapeutic efficacy and provides a blueprint for translational cancer biology workflows.

• Ensuring BET Inhibition Specificity: Lab Scenarios with (-)-

  2026-04-18

  This article explores how (-)-JQ1 (SKU A8181) empowers life science researchers to resolve key experimental challenges in BET bromodomain studies. Through scenario-driven Q&A, it demonstrates how A8181's rigorous control properties enhance data reliability, reproducibility, and workflow confidence in epigenetics and cancer biology research.

• Cisapride (R 51619): Precision Tools for Cardiac Electrophys

  2026-04-17

  Cisapride (R 51619) unlocks high-fidelity modeling of cardiac electrophysiology and drug-induced arrhythmias by leveraging its dual 5-HT4 agonism and hERG channel inhibition. This guide distills best practices, troubleshooting, and advanced workflows—empowering researchers to maximize assay precision, especially in iPSC-derived cardiomyocyte platforms.

• AIBP-LRP2–HDL Axis Regulates CXCR4+ Capillary Expansion in I

  2026-04-16

  This study uncovers a mechanistic pathway where AIBP and LRP2 mediate high-density lipoprotein (HDL) uptake, thereby restricting the expansion of CXCR4+ stem-like capillary endothelial cells and limiting collateral vessel formation in ischemic vascular disease. The findings offer a new perspective on the regulation of collateral circulation and potential therapeutic targets for revascularization in peripheral artery disease.

• Lysis Buffer for Mouse Tail Genotyping: Mechanism & Evidence

  2026-04-15

  Lysis buffer, a key component of rapid genotyping kits, enables efficient genomic DNA release from mouse tail tissue. Optimized for proteinase K digestion, it supports high-integrity DNA extraction suitable for genetic analysis. APExBIO’s H1002 buffer offers validated stability and reliability for preclinical research workflows.

• AQP9 Downregulation Drives Aggression in KRASG12V Colorectal

  2026-04-14

  This study uncovers how reduced aquaporin 9 (AQP9) expression in KRASG12V mutant colorectal cancer (CRC) correlates with increased tumor proliferation and reduced apoptosis. Integration of molecular, pathological, and bioinformatics analyses highlights the ZHX2–AQP9 axis as a potential target for therapeutic intervention in aggressive CRC subtypes.

• Phenacetin (SKU B1453): Reliable Probe for In Vitro PK Studi

  2026-04-13

  This article addresses common laboratory challenges in pharmacokinetic studies using Phenacetin (SKU B1453), focusing on its role as a high-purity, research-grade probe. Drawing from recent organoid model advances and APExBIO’s rigorous quality control, we provide scenario-driven, evidence-based guidance for assay optimization, solubility management, and product selection.

• Strategic Use of A-1210477 in MCL-1-Driven Cancer Research

  2026-04-13

  This article explores the mechanistic and translational landscape of MCL-1 inhibition in cancer research, focusing on the selective small-molecule inhibitor A-1210477. It synthesizes recent advances in mitochondrial apoptosis understanding, experimental best practices, and the evolving therapeutic context—offering strategic guidance for translational researchers aiming to leverage MCL-1 dependency in oncology.

• Nilotinib (AMN-107): Optimizing BCR-ABL Signaling Research

  2026-04-12

  Nilotinib (AMN-107) enables high-precision dissection of BCR-ABL and KIT signaling in chronic myeloid leukemia and gastrointestinal stromal tumor research. Explore workflow refinements, troubleshooting strategies, and advanced use-cases that leverage this selective tyrosine kinase inhibitor’s unique strengths for reproducibility and mechanistic clarity.

15031 records 1/1003 page Next 12345 下5页 Last page